Alcoholism Clinical Trial
— CRAVING-NETOfficial title:
Study of the Neural Substrates of Alcohol Craving by High-resolution Electroencephalography
Verified date | November 2023 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Alcohol is the most consumed psychoactive substance in France and is responsible for 49,000 deaths per year in the country. Addictions, characterized by "the repeated impossibility of controlling a behavior and the continuation of this behavior despite the knowledge of its negative consequences", are a major public health issue in France and worldwide. Alcohol dependence (DSM-5 moderate to severe use disorder) is a chronic behavioral disorder, whose main characteristic is its high and prolonged risk of "relapse", i.e. the resumption of problematic consumption after a period of improvement (abstinence or reduction). One of the main components of addiction is "craving", which can be defined as the irrepressible desire to use a substance (DSM-5, American Psychiatric Association). To date, despite functional imaging studies (fMRI), the brain mechanisms involved in craving remain poorly understood. In recent years, a new neuroimaging device has become available, both in research and in clinical settings: high-resolution electroencephalography (HRE). This non-invasive method allows to observe brain activity at the millisecond level. The objective of the CRAVING-NET project is to better understand brain function in alcohol addiction, and in particular in craving.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | November 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 30 Years to 60 Years |
Eligibility | Inclusion Criteria: Patients (N=20): - Subject with moderate to severe DSM-5 alcohol use disorder hospitalized for withdrawal as part of their routine care. - Presence of spontaneous and/or in response to environmental stimuli (induced) self-described episodes of craving. - Males with age = 30 years and = 60 years; - Normal or corrected-to-normal visual acuity (declarative); - Right-handed; Healthy control volunteers (N=40): - Men with age = 30 years and = 60 years; - Normal or corrected-to-normal visual acuity; - Right-handed; - Smoker (current user, N=20) or Nonsmoker (never smoked, N=20); - Alcohol consumption below the low-risk drinking threshold (<10 standard drinks per week) Exclusion Criteria: For all subjects: - Alcohol use in the 24 hours prior to the experiment; - Consumption of psychoactive substances other than tobacco and alcohol (positive urine test). - Presence of a contraindication related to the MRI technique - Being under legal protection, and/or deprived of freedom; - Not mastering the French language (written and oral); - Inability to understand the information given on the study and/or to carry out the experimental task. For patients: - Presence of cognitive impairment (MoCA score < 25) - Absence of spontaneous or induced craving episodes - Decompensated cirrhosis: ascites and/or encephalopathy and/or jaundice and/or recent hemorrhage For healthy control volunteers: - Significant medical or surgical history related to the central nervous system; - Current use (< 30 days) of drugs affecting the central nervous system belonging to the class of antidepressants, sleeping pills and/or anxiolytics. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Source connectivity within large-scale brain networks | Difference in source connectivity within large-scale brain networks following the induction of craving episodes between alcohol-dependent patients and matched healthy participants (smokers and non-smokers). Source connectivity is measured by the strength of connections between brain regions (ratio value between 0 (no communication) and 1 (strong communication)). | 1 day | |
Secondary | Variation in source connectivity based on AUQ | Significant difference in source connectivity between patients and volunteers based on Alcohol Urge Questionnaire (AUQ,easures craving in patients with alcohol dependence; Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by averaging the item scores. Higher scores reflect greater craving. | 1 day | |
Secondary | Variation in source connectivity based on OCDS | Significant difference in source connectivity between patients and volunteers based on Obsessive Compulsive Drinking Scale (OCDS , allows to obtain a global alcohol appetite score and to evaluate the craving, in 14 items with a compulsion sub-score and an obsessional sub-score. Higher scores reflect greater craving. | 1 day | |
Secondary | Variation in source connectivity based on psychological state | Significant difference in source connectivity between patients and volunteers based on Hospital Anxiety and Depression scale (HAD , allows to obtain a anxiety score and a depression score to evaluate psychological state. Two subscores, one for anxiety and one for depression. Higher sub-scores reflect higher anxiety or depression. | 1 day | |
Secondary | Correlation between brain networks estimated by HRE and AUQ and OCDS scores | Correlation between brain networks estimated by EEG-HR and AUQ and OCDS scores at 6 months only in patients | 6 months | |
Secondary | Correlation between EEG-HR and fMRI networks at inclusion | Correlation between EEG-HR and fMRI networks at inclusion in patients and healthy volunteers | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 |